EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effects of Oral Single‐Dose Empagliflozin on Urinary Glucose, Serum β‐Hydroxybutyrate, and Plasma Empagliflozin Concentrations in Healthy Adult Dogs

Andrea D Plá Gutierrez iD, M Lynne O'Sullivan iD, Etienne Côté iD, Sandra McConkey iD, Butch KuKanich iD, Stephanie E Martinez iD

Journal of Veterinary Pharmacology and Therapeutics · 2026-07 · 49 (4) · 427-432

DOI: 10.1111/jvp.70066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 19.03.2026. Verfasst von Andrea D Plá Gutierrez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Companion Animals, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, 3-Hydroxybutyric Acid, Glucose. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Arthur L. Irving Family Foundation, Atlantic Veterinary College, University of Prince Edward Island.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Empagliflozin is a sodium‐glucose cotransporter‐2 inhibitor used for treating humans with heart failure, among other conditions. This drug could have applications in veterinary cardiology, but whether empagliflozin has biological effects in dogs when administered at dosages approximating human therapeutic dosages is unknown. This study investigated whether empagliflozin (target dosage, 0.3 mg/kg) could produce significant increases in urinary glucose concentrations and measurable plasma drug concentrations, without increasing serum β‐hydroxybutyrate (β‐HA) concentrations in dogs. Six healthy, privately‐owned dogs weighing 22–36 kg were studied prospectively. Urinary glucose, serum β‐HA, and plasma empagliflozin concentrations were measured 0 h, 6 h, 12 h, 24 h, 48 h, and 72 h after single‐dose oral administration of 10 mg empagliflozin. The dosage administered was 0.28–0.45 mg/kg. Mean urinary glucose concentration peaked at 24 h (8,041 mg/dL) before returning to baseline (< 40 mg/dL) at 72 h ( p < 0.001). Serum β‐HA concentrations remained within the reference interval for dogs (< 2.1 mg/dL). Plasma drug concentrations at 24 h were 13 times greater than the reported human in vitro IC50. The half‐life was 4.4–6 h. Oral empagliflozin 0.28–0.45 mg/kg produced glucosuria and measurable plasma drug concentrations in healthy dogs, without ketonemia, after a single dose.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl Compounds3-Hydroxybutyric AcidGlucoseAnimalsDogsAdministration, OralFemaleMaleGlycosuriaSodium-Glucose Transporter 2 InhibitorsHalf-Life

Stichwörter der Autor:innen

cardiovascularglucosuriaheartsodium‐glucose cotransporter‐2 inhibitorveterinary

Substanzen

GlucosidesBenzhydryl Compoundsempagliflozin3-Hydroxybutyric AcidGlucoseSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Companion Animals, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada.
  • Department of Biomedical Sciences, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, Prince Edward Island, Canada.
  • Department of Anatomy & Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA.
  • Department of Veterinary Clinical and Life Sciences, College of Veterinary Medicine, Utah State University, Logan, Utah, USA.

ORCID-Profile: Andrea D Plá Gutierrez, M Lynne O'Sullivan, Etienne Côté, Sandra McConkey, Butch KuKanich, Stephanie E Martinez

Förderung

  • Arthur L. Irving Family Foundation
  • Atlantic Veterinary College
  • University of Prince Edward Island

Zitieren

APA

Plá Gutierrez, A. D., O'Sullivan, M. L., Côté, E., McConkey, S., KuKanich, B., & Martinez, S. E. (2026). Effects of Oral Single‐Dose Empagliflozin on Urinary Glucose, Serum β‐Hydroxybutyrate, and Plasma Empagliflozin Concentrations in Healthy Adult Dogs. Journal of Veterinary Pharmacology and Therapeutics, 49(4), 427-432. https://doi.org/10.1111/jvp.70066

Vancouver

Plá Gutierrez AD, O'Sullivan ML, Côté E, McConkey S, KuKanich B, Martinez SE. Effects of Oral Single‐Dose Empagliflozin on Urinary Glucose, Serum β‐Hydroxybutyrate, and Plasma Empagliflozin Concentrations in Healthy Adult Dogs. Journal of Veterinary Pharmacology and Therapeutics. 2026;49(4):427-432. doi:10.1111/jvp.70066

BibTeX
@article{PlGutierrez2026,
  author = {Plá Gutierrez, Andrea D and O'Sullivan, M Lynne and Côté, Etienne and McConkey, Sandra and KuKanich, Butch and Martinez, Stephanie E},
  title = {Effects of Oral Single‐Dose Empagliflozin on Urinary Glucose, Serum β‐Hydroxybutyrate, and Plasma Empagliflozin Concentrations in Healthy Adult Dogs},
  journal = {Journal of Veterinary Pharmacology and Therapeutics},
  year = {2026},
  volume = {49},
  number = {4},
  pages = {427--432},
  doi = {10.1111/jvp.70066}
}
Kostenlos starten →